Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:20 EDT
SunTrust analyst John Boris says that data on AbbVie's (ABBV) UPAD for rheumatoid arthritis shows that its efficacy "appears competitive" with that of Pfizer's (PFE) Xeljanz/XR. The analyst says that the data increases his confidence in AbbVie's opportunity in RA. He keeps a $95 price target and a Buy rating on the shares.
News For ABBV;PFE From the Last 2 Days
Sep 22, 2017 | 07:35 EDT
Notable call activity was cited Thursday in AMD (AMD), Microsoft (MSFT), Intel (INTC), AbbVie (ABBV), Kinder Morgan (KMI), Golar LNG (GLNG), Hasbro (HAS), and Michaels (MIK).